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Although fibrinolysis has improved survival of patients after myocardial infarction (MI), such
therapy is less likely to be administered to patients with diabetes. Furthermore, these patients
present later (15 min) than nondiabetics. Moreover, even with the use of early potent
fibrinolytic agents, patients with diabetes continued to suffer excessive morbidity and
mortality. This finding is not related to the ability of fibrinolytic agents to restore complete
reperfusion or increased risk of reocclusion of the infarct-related artery. Instead, the impaired
ventricular performance at the noninfarct areas and metabolic derangements during the acute
phase of MI may account for the adverse outcome. The efficacy of percutaneous coronary
revascularization procedures for treatment of acute MI requires further evaluation. Thera-
peutic approaches should consider correcting these abnormalities to afford greater survival
benefit for this subset of high-risk patients. (J Am Coll Cardiol 2000;35:563–8) © 2000 by
the American College of Cardiology
The Framingham study has clearly demonstrated that car-
diovascular mortality was heightened among patients with
diabetes. This trend is particularly evident following acute
myocardial infarction (AMI) (1). Although the use of
fibrinolytic therapy in the treatment of AMI has resulted in
a considerable improvement of survival, diabetes remained
an important independent predictor for mortality (2). This
review will examine the issues that may account for this
unfavorable prognosis and promising avenues to further
improve outcomes.
OVERVIEW OF FIBRINOLYSIS
In a major international trial involving more than 40,000
patients designed to evaluate four fibrinolytic strategies for
the treatment of AMI, 30-day mortality was 6.2% among
patients without diabetes and 10.5% among patients with
diabetes (Fig. 1). Indeed, by pooling the data from several
large fibrinolytic trials with a total of more than 80,000
patients, the one-month mortality was increased by 1.7
times among diabetics. Notably, mortality was highest
among those treated with insulin. Mortality for patients
treated with insulin was at least 1.3 times greater than for
noninsulin diabetics. In fact, the difference in mortality
between patients with and without diabetes continues to
increase after 30 days. By the end of the first year, the
relative risk for mortality for patients with diabetes has risen
from ;1.4 to ;1.6 times (3).
Impaired delivery of care. Fibrinolytic therapy has un-
doubtedly improved outcome of patients after AMI (4,5).
Perhaps less known is the fact that fibrinolysis saved 37 lives
per 1,000 patients with diabetes at 35 days, compared with
15 per 1,000 patients without diabetes (6). Thus, the
absolute benefit is more than doubled for fibrinolytic ther-
apy among diabetics. Despite its tremendous benefit, dia-
betics were less likely to receive fibrinolytic therapy (7), as
evident in the Survival and Ventricular Enlargement
(SAVE) Study. This trial was designed to evaluate the
efficacy of captopril in reducing mortality and morbidity in
survivors of AMI with baseline left ventricular dysfunction.
Use of fibrinolytic therapy was left to the discretion of the
attending physician. Of 2,231 patients enrolled, fibrinolytic
therapy was administered in 733 (32.9%). Among various
epidemiological parameters studied, the presence of diabetes
emerged as an independent variable for not using fibrino-
lytic therapy (Fig. 2). Importantly, these findings extend
beyond the context of a clinical trial. In a recent report from
a large national AMI registry (8), 272,651 patients with an
AMI enrolled from almost 1,500 hospitals during the
period of June 1994 to July 1996. Of these, 84,663 (31%)
were considered to be eligible for reperfusion therapy.
Although the proportion of patients (76%) who actually
received this mode of treatment was greater than the SAVE
study (7), the factors associated with failure to use reperfu-
sion therapy were quite similar. Indeed, using univariate
analysis, the odds for patients with diabetes mellitus to
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receive reperfusion therapy was almost half compared with
nondiabetics. The presence of diabetes mellitus remained as
an independent predictor for a lower likelihood for reper-
fusion therapy in a multivariate statistical model (OR 0.67;
95% confidence interval [CI], 0.52 to 0.87). This unfavor-
able trend was also observed in a nationwide French survey
(37% vs. 46%, for diabetic and nondiabetic patients receiv-
ing reperfusion therapy, respectively; p 5 0.001) (9) and the
United Kingdom (37% vs. 54%, for diabetic and nondiabetic
patients receiving reperfusion therapy, respectively; p ,
0.05) (10). However, as with several of these clinical studies,
the reasons for this finding are largely unknown and
probably attributed to numerous factors, such as atypical or
late presentation and undue concern regarding the adverse
effects of fibrinolysis. In the Global Utilization of Streptoki-
nase and Tissue Plasminogen Activator for Occluded Cor-
onary Arteries (GUSTO-I) study (3), there was only a
marginal increase in moderate bleeding complications (13%
vs. 11%) without an increased risk in major bleeding rates.
More importantly, the risk of intracranial hemorrhage was
similar between patients with and without diabetes (0.6% vs.
0.7%; p . 0.05). Furthermore, intraocular hemorrhage did
not occur in any of the 6,011 diabetic patients although
there was one patient with periorbital hematoma from a fall.
So the upper 95% CI for intraocular hemorrhage in patients
with diabetes was 0.05% (11). Hence, administration of
fibrinolytic agents is not associated with increased compli-
cations. When there are no usual contraindications, physi-
cians should be encouraged to treat diabetic patient with
fibrinolytic agents for AMI (12).
Another major drawback for diabetic patients was that
they were receiving fibrinolytic therapy (15 min later [3]).
Although the reason for this delay is unclear, the impaired
sensation of pain may be contributory (13). From the pooled
data of almost 69,000 patients, the Fibrinolytic Therapy
Trialists’ Group (6) found that mortality was 1% higher for
every hour lag in treatment. As such, a rational approach in
improving outcome of diabetic patients with AMI is to
educate these patients on the importance of early presenta-
tion and atypical manifestations of AMI (14). Furthermore,
oral hypoglycemic agents are known to cause repolarization
abnormalities on the resting electrocardiogram. In particu-
lar, some animal studies suggest (15,16) that the amplitudes
of ST-segment elevation and T-wave peaking may be
reduced with these medications and, therefore, lowered the
sensitivity of the electrocardiogram in identifying such
patients with AMI. Physicians are to maintain a high index
of suspicion to recognize these patients. However, the
success of this strategy does not depend only on the sincere
efforts of healthcare providers and extensive public educa-
tion programs. To further improve outcomes of this subset
of high-risk patients, other barriers of health care delivery,
such as financial and logistical, must be overcome by an
effective national health policy (17).
Possible impaired fibrinolysis. In addition to bias against
the use of fibrinolytic agents and later presentation, patients
with diabetes have enhanced platelet activity, elevated pro-
coagulant levels and impaired intrinsic fibrinolysis (18).
These abnormalities are believed to account for, at least in
part, the deleterious clinical course of diabetic patients with
AMI as the efficacy of fibrinolytic agents may be reduced.
The importance of a prompt response to fibrinolysis in
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Figure 1. Kaplan-Meier estimates of cumulative mortality by
diabetes status in the GUSTO-I Study (3).
Figure 2. Odds ratio in a multiple logistic regression model for
predicting the use of fibrinolysis in the SAVE Trial. SAVE 5
Survival and Ventricular Enlargement Study.
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achieving early and complete reperfusion of the infarct-
related artery is clearly demonstrated by the data from a
large angiographic study of patients with AMI (19). Pa-
tients with Thrombolysis in Myocardial Infarction (TIMI)
grade 3 flow showed a substantial reduction in 30-day
mortality compared with those with TIMI flow grades 0 or
1, with an odds ratio of 0.46 (95% CI, 0.25–0.86). By
pooling the results of 4,687 patients undergoing coronary
angiography after myocardial infarction (MI), mortality was
lowest among those with TIMI grade 3 flow (3.7%),
intermediate among those with TIMI grade 2 flow (6.6%)
and greatest among those with TIMI grade 0 or 1 flow
(9.2%) at 90 min (20).
However, there was little difference in the TIMI flow
grades between patients with and without diabetes (21).
This finding was, in some ways, unexpected, and, therefore,
the excess mortality associated with patients with diabetes
cannot be attributed to reduced patency response to fibrino-
lytic therapy. However, TIMI flow may not accurately
reflect myocardial flow among patients with diabetes. Un-
derlying endothelial dysfunction (22,23) and diminished
myocardial flow reserve (24) may contribute to poorer
outcomes despite similar TIMI flow grades.
In addition to the similar TIMI flow grades, there were
no differences in the rates of angiographic reocclusion (21)
and reinfarction (3) between patients with and without
diabetes (Fig. 3). Nonetheless, it must be recognized that in
the angiographic study, the proportion of patients who died
before follow-up angiography was almost three-fold higher
for diabetic patients (21). Since these patients were more
likely to suffer from reocclusion, the question as to whether
angiographic reocclusion rates were between patients with
and without diabetes remains to be answered conclusively.
Likewise, in the clinical trial, patients with diabetes may be
more inclined to suffer from silent reinfarction and may have
avoided detection. But the contribution of this premise to
account for the unfavorable outcomes of diabetic patients is
uncertain. These potential limitations underscore the prob-
lems associated with retrospective subgroup analysis and the
importance of a prospective study to confirm these obser-
vations.
In contrast, recurrent ischemia occurred more commonly
among diabetics (22% vs. 20%, p , 0.001) (3). The inability
to maintain vessel patency is known to result in drastic
consequences, including higher complication, revasculariza-
tion and mortality rates (25,26). This problem may be
related to the poorer outcome of patients with patients. As
the increased rate of recurrent ischemia may be due to
enhanced thrombogenicity among diabetics, more potent
antithrombotic agents may be useful and are being evaluated
in clinical studies.
Left ventricular function. Although some investigators
(27) regarded left ventricular ejection fraction as a critical
determinant for outcome, global left ventricular systolic
function was similar between patients with and without
diabetes after AMI (21,28). This finding was consistent in
both the early and late phase of the in-hospital period. Not
surprisingly, other investigators (29) have suggested that left
ventricular ejection fraction tended to approach 50% in
various treatment groups in large clinical trials, or the “50%
rule,” which precluded meaningful comparison. There was
also no difference in systolic function between diabetic and
nondiabetic patients (21,30). Recovery of function of these
segments during the late hospitalization period was compa-
rable. In addition, there was no difference in infarct size
between these two groups of patients (3). These findings
were contrary to the hypothesis that sulfonylurea induced
impairment of ischemic preconditioning, which resulted in
greater myocardial damage and higher mortality (31–33).
Several factors may account for the disparity. Although
ischemic preconditioning was well demonstrated in a num-
ber of animal and angioplasty models, its significance
among humans has been questioned (34,35). Furthermore,
the interaction between ATP-sensitive potassium channels
and sulfonylureas is complex and varied.
The crucial difference in left ventricular function was that
the hyperkinetic response of the noninfarcted areas was
attenuated in diabetic patients (21,30). This observation,
therefore, may explain, to some extent, the greater mortality
(36). During the acute phase of AMI, various pathophysi-
ological changes increase the contractility of the myocar-
dium at the noninfarcted zone. However, this response is
impaired among diabetic patients and may be related to
endothelial, microcirculation and cellular dysfunction (col-
lectively known as diabetic “cardiomyopathy” [37]), auto-
nomic neuropathy and multivessel disease. After the acute
phase of AMI, and with the resolution of the abnormal
pathophysiological stresses, the myocardial response at the
noninfarct zone normalizes, and contractility was similar
between diabetic and nondiabetic patients (21).
MECHANICAL REPERFUSION STRATEGIES
The advent of percutaneous transluminal coronary angio-
plasty (PTCA) has broadened the horizon for the treatment
Figure 3. In-hospital angiographic reocclusion and 30-day rein-
farction rates after fibrinolysis in the GUSTO-I Study.
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of coronary artery disease. With reocclusion of the infarct
artery as a major problem fibrinolysis for AMI, the TIMI II
(38) trial randomized 3,339 patients to an invasive or
conservation strategy. All patients were treated with tissue-
plasminogen activator. Those receiving the invasive strategy
underwent coronary angiography within 18 to 48 h of
randomization, and PTCA was performed on the infarct
artery when the anatomy was appropriate. Otherwise, cor-
onary artery bypass grafting was recommended. In contrast,
patients randomized to the conservative strategy underwent
these procedures only when there was spontaneous or
provoked myocardial ischemia. Among patients with diabe-
tes, the 42-day mortality was substantially higher for those
in the invasive strategy (14.8% vs. 4.2%; p , 0.001).
Conversely, there was no difference in mortality among
nondiabetic patients randomized to invasive or conservative
strategies (3.8% vs. 3.4%), and, hence, the investigators
cautioned the use of the invasive approach for patients with
diabetes.
With improvement in techniques and operator experi-
ence, primary angioplasty for the treatment of AMI has
been shown to improve outcome compared with fibrino-
lytic therapy (39) by early and complete restoration of
antegrade flow. The expanded lumen, as compared with
fibrinolytic therapy, also resulted in lower rates of recur-
rent ischemia (28). In a subanalysis of one of these trials
(40), survival among patients with diabetes was improved
after primary angioplasty. But the effect was attributed to
the greater number of older patients. More recently, the
preliminary results of 159 patients with diabetes who
underwent direct angioplasty for AMI were encouraging
(41). The initial success rate was high (98%) with low
in-hospital event rates and short hospital stay (mean of
2.7 days). At the end of 12 months, mortality was 2.2%
and reinfarction was 9%, and 86% of patients were free of
adverse events. However, more rigorous application of
this therapeutic intervention afforded only modest benefit
(42), regardless of diabetic status (43), and, hence, its
application requires further evaluation.
Coronary stenting has improved the results of PTCA
(44,45). Primary stenting for AMI has also been shown
to be superior to conventional balloon angioplasty (46 –
48). Therefore, this approach may be appropriate for
patients with diabetes. In a small series of 104 patients
(49), the immediate angiographic results of patients with
AMI who underwent coronary stenting were similar
between patients with and without diabetes. However,
patients with diabetes have a substantially higher rates of
stent thrombosis (18% vs. 1%; p 5 0.003). At the end of
a year, survival was considerably lower among patients
with diabetes (89% vs. 99%; p 5 0.04). However, GP
IIb/IIIa inhibitors, which were not routinely used in this
study, may improve outcomes of this high-risk group of
patients.
IMPAIRED GLUCOSE UTILIZATION
During periods of increased workload (50) or ischemia (51),
glucose tends to undergo anaerobic metabolism. To main-
tain myocardial function, uptake of glucose has to be
increased (52) by a process facilitated by the principal
transporter, GLUT4. When there is insulin deficiency,
GLUT-4 translocation is correspondingly reduced, and
there is a shift towards fatty acid metabolism, which is
rapidly generated from increased sympathetic activity (53).
These aberrations result in increased oxygen consumption
and subsequent deterioration of myocardial function. Fur-
thermore, free fatty acids (FFA) may reduce contractility,
and subsequent production of free radicals will lead to
membrane instability and promote arrhythmias (54). This
vicious cycle will result in loss of membrane integrity and
eventual cell death.
The basis for the use of glucose insulin potassium (GIK)
solution for the treatment of AMI may be related to
myocardial protection, in particular, before and after reper-
fusion (55). With the availability of exogenous glucose,
insulin and potassium, adenosine triphosphate (ATP) is
generated more efficiently and lipolysis is inhibited and,
hence, lowers the amount of FFA (56).
By pooling the results of nine early studies, adminis-
tration of GIK resulted in a laudable 28% lowering of
in-hospital mortality among 1,932 patients (57). Indeed,
when the concentration of GIK was sufficiently high
enough to suppress fatty acid levels in four of these trials,
there was a substantial 48% mortality reduction. To
further complicate the issue, the preliminary results of a
Polish clinical trial consisting of 954 patients randomized
to 24-hour infusion of low-dose GIK or saline cast doubt
again on the efficacy of this therapy. Total mortality rates
were considerably higher among those receiving GIK at
35 days (8.9% vs. 4.8%; p 5 0.01) and six months (11.1%
vs. 6.5%; p 5 0.01) (58). There was no significant
difference in cardiac mortality or events. The lack of
beneficial effect may be related to the dose and duration
of GIK infusion.
In the Diabetic Patients with Acute Myocardial Infarc-
tion (DIGAMI) Study (59), 306 of 620 patients were
randomized to receive insulin-glucose infusion followed by
multidose subcutaneous insulin and the remaining 314
patients to conventional therapy. At three months, the level
of glycosylated hemoglobin was lower than the control
group (7% vs. 7.5%; p , 0.01). By the end of the first year,
there was a 29% reduction in mortality. The benefit,
amounting to lowering mortality by 52%, was greatest
among patients with low cardiovascular risk profile and no
previous insulin treatment. Although these results are ex-
tremely encouraging, validation from a prospective ade-
quately powered clinical trial using current techniques
would be required before this treatment strategy could be
widely adopted.
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Conclusions. Through a variety of direct and indirect
pathophysiological mechanisms, patients with diabetes are
associated with a substantially worse outcome after AMI,
even in this current era of fibrinolysis. This observation
could not be explained by the patency response to fibrino-
lytic agents. In fact, survival benefit was similar in patients
with and without diabetes when treated with accelerated
tissue plasminogen activator compared with streptokinase
(3). More potent fibrinolytic agents will likely achieve
similar infarct vessel reperfusion rates between diabetic and
nondiabetic patients. An important clinical difference is the
rate of recurrent ischemia (3). More potent antithrombotic
agents are likely to further improve outcomes of these
patients.
Another crucial concept in the management of patients
with AMI is to keep the infarct artery open to afford better
survival. Although patency of the infarct artery could be
rapidly achieved with PTCA, routine revascularization of
patients with diabetes receiving fibrinolytic therapy may be
detrimental. On the other hand, PTCA is likely to improve
survival of patients with recurrent ischemia, especially when
left ventricular systolic function is impaired (60). Direct
angioplasty may provide similar survival benefit for patients
with and without diabetes, particularly with the concomi-
tant use of coronary stenting and GP IIb/IIIa inhibition.
Beyond restoring infarct-artery reperfusion, other strate-
gies of preserving myocardial and correcting metabolic
derangements during the peri-infarctional period may fur-
ther improve outcome. These promising treatment modal-
ities are being evaluated in clinical studies. Whether the use
of sulfonylureas is associated with adverse outcomes among
patients with diabetes remains uncertain (61).
Among diabetic patients, the process of atherosclerosis is
more diffuse (21). Cardiovascular mortality among patients
with type II diabetes without prior MI was reported to be as
high as nondiabetic patients with previous infarction in a
seven-year follow-up Finnish study (62). Therefore, aggres-
sive risk factor modification strategies, even in the absence
of established coronary heart disease, should be adopted
early. In conclusion, despite substantial advances in the
treatment of AMI over the past several years, effective
therapeutic modalities are still desperately needed to im-
prove the outcomes of this high-risk group of patients.
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